ANBL1531: A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Grant

Total Award Amount

  • 22000.00
  • Direct Costs

  • 18333.00
  • Sponsor Award Id

  • Contributor

  • Matthew Kutny M.D.   Principal Investigator